Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard(R)
Xenikos announced the FDA has approved an investigational new drug application to initiate a U.S.-based clinical Phase 3 registration trial in order to test efficacy of T-Guard for treating SR-aGVHD in patients following allogeneic stem cell transplantation. June 11, 2019